CLIMB BIO INC. - COMM

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

15 авг 2022 06:10:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Provides ETX-810 Program Update

02 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

18 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

07 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

27 июн 2022 16:01:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

16 май 2022 06:10:00 Источник Nasdaq GlobeNewswire

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

25 апр 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

05 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

Eliem Therapeutics to Present at Stifel’s 2022 CNS Days

21 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

07 мар 2022 16:10:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 фев 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022

07 фев 2022 07:00:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones

18 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

08 ноя 2021 16:01:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics to Participate at Four Upcoming Investor Conferences

04 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Reports Second Quarter Financial Results

13 сен 2021 16:10:00 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

12 авг 2021 21:06:11 Источник Nasdaq GlobeNewswire

Eliem Therapeutics Announces Pricing of Initial Public Offering

09 авг 2021 22:33:09 Источник Nasdaq GlobeNewswire